Cited by 87Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.

Biomarkers for Alzheimer’s Disease

Guzman-Martinez, Leonardo, Maccioni, Ricardo B., Farías, Gonzalo A., Fuentes, Patricio, Navarrete, Leonardo P.·2019·Current Alzheimer Research

DOI 10.2174/1567205016666190517121140

Open this paper in CoChat — free account

Abstract

Alzheimer´s disease (AD) and related forms of dementia are increasingly affecting the aging population throughout the world, at an alarming rate. The World Alzheimer´s Report indicates a prevalence of 46.8 million people affected by AD worldwide. As population ages, this number is projected to triple by 2050 unless effective interventions are developed and implemented. Urgent efforts are required for an early detection of this disease. The ultimate goal is the identification of viable targets for the development of molecular markers and validation of their use for early diagnosis of AD that may improve treatment and the disease outcome in patients. The diagnosis of AD has been difficult to resolve since approaches for early and accurate detection and follow-up of AD patients at the clinical level have been reported only recently. Some proposed AD biomarkers include the detection of pathophysiological processes in the brain in vivo with new imaging techniques and novel PET ligands, and the determination of pathogenic proteins in cerebrospinal fluid showing anomalous levels of hyperphosphorylated tau and low Aβ peptide. These biomarkers have been increasingly accepted by AD diagnostic criteria and are important tools for the design of clinical trials, but difficulties in accessibility to costly and invasive procedures have not been completely addressed in clinical settings. New biomarkers are currently being developed to allow determinations of multiple pathological processes including neuroinflammation, synaptic dysfunction, metabolic impairment, protein aggregation and neurodegeneration. Highly specific and sensitive blood biomarkers, using less-invasive procedures to detect AD, are derived from the discoveries of peripheric tau oligomers and amyloid variants in human plasma and platelets. We have also developed a blood tau biomarker that correlates with a cognitive decline and also with neuroimaging determinations of brain atrophy.

Integrity signals

Registry

Crossref · 10.2174/1567205016666190517121140

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expression
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Neuroinflammation in Parkinson's disease
Hirsch, E. C., Vyas, S., & Hunot, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70065-7 · Cited by 657
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
A blood based 12-miRNA signature of Alzheimer disease patients
Leidinger, P., Backes, C., Deutscher, S., Schmitt, K., Mueller, S. C., Frese, K., Haas, J., Ruprecht, K., Paul, F., Stähler, C., et al. (2013) · Genome biology · doi:10.1186/gb-2013-14-7-r78 · Cited by 509
The molecular bases of Alzheimer’s disease and other neurodegenerative disorders
Maccioni, R. B., Muñoz, J. P., & Barbeito, L. (2001) · Archives of Medical Research · doi:10.1016/s0188-4409(01)00316-2 · Cited by 474
Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease
Doecke, J. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1282 · Cited by 422
Role of microtubule-associated proteins in the control of microtubule assembly
Maccioni, R. B., & Cambiazo, V. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.4.835 · Cited by 413
Self-citation
Connexin-based gap junction hemichannels: Gating mechanisms
Sáez, J. C., Retamal, M. A., Basilio, D., Bukauskas, F. F., & Bennett, M. V. L. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.01.014 · Cited by 411
Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile
Winston, C. N., Goetzl, E. J., Akers, J. C., Carter, B. S., Rockenstein, E. M., Galasko, D. R., Masliah, E., & Rissman, R. A. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.04.001 · Cited by 379
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370
Neuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.10.001 · Cited by 351
Self-citation
Intracerebral Production of Tumor Necrosis Factor-α, a Local Neuroprotective Agent, in Alzheimer Disease and Vascular Dementia
Tarkowski, E., Blennow, K., Wallin, A., & Tarkowski, A. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020568013953 · Cited by 349
The Revitalized Tau Hypothesis on Alzheimer's Disease
Maccioni, R. B., Farias, G. A., Morales, I., & Navarrete, L. P. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.03.007 · Cited by 316
Self-citation
Tau PET imaging: present and future directions
Saint‐Aubert, L., Lemoine, L., Chiotis, K., Leuzy, A., Rodriguez‐Vieitez, E., & Nordberg, A. K. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0162-3 · Cited by 300
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRx · doi:10.1602/neurorx.1.2.226 · Cited by 273
Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 load
Wiltfang, J., Esselmann, H., Bibl, M., Hüll, M., Hampel, H. J., Kessler, H., Frölich, L., Schröder, J., Peters, O., Jessen, F., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04404.x · Cited by 269
Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome
Tatebe, H., Kasai, T., Ohmichi, T., Kishi, Y., Kakeya, T., Waragai, M., Kondo, M., Allsop, D., & Tokuda, T. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0206-8 · Cited by 265
Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M. K., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 258
MicroRNA-137/181c Regulates Serine Palmitoyltransferase and In Turn Amyloid β, Novel Targets in Sporadic Alzheimer's Disease
Geekiyanage, H., & Chan, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3883-11.2011 · Cited by 254
Proinflammatory cytokines, sickness behavior, and Alzheimer disease
Holmes, C., Cunningham, C. M., Zotova, E., Culliford, D. J., & Perry, V. H. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ae07 · Cited by 250
Inhibition of tau phosphorylating protein kinase cdk5 prevents β‐amyloid‐induced neuronal death
Alvarez, A. R., Toro, R., Cáceres, A., & Maccioni, R. B. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01279-x · Cited by 228
Self-citation
Mechanisms of Protein Seeding in Neurodegenerative Diseases
Walker, L. C., Diamond, M. I., Duff, K. E., & Hyman, B. T. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1453 · Cited by 226
Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease
Peskind, E. R., Griffin, W. S. T., Akama, K. T., Raskind, M. A., & Eldik, L. J. V. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00048-1 · Cited by 215
Detection of Misfolded Aβ Oligomers for Sensitive Biochemical Diagnosis of Alzheimer’s Disease
Salvadores, N., Shahnawaz, M., Scarpini, E. A., Tagliavini, F., & Soto, C. A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.031 · Cited by 205
Age and amyloid effects on human central nervous system amyloid‐beta kinetics
Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24454 · Cited by 200
BDNF, TNFα, HSP90, CFH, and IL-10 Serum Levels in Patients with Early or Late Onset Alzheimer's Disease or Mild Cognitive Impairment
Gezen-Ak, D., Dursun, E., Hanağası, H., Bilgiç, B., Lohman, E., Araz, Ö. S., Atasoy, İ. L., Alaylıoğlu, M., Önal, B., Gürvit, H., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130497 · Cited by 188
Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals
Lombardi, V., Garcı́a, M., Rey, L., & Cacabelos, R. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00046-6 · Cited by 182
MRI morphometry in Alzheimer’s disease
Matsuda, H. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.003 · Cited by 177
Lipid Biomarkers in Alzheimer's Disease
Zarrouk, A., Debbabi, M., Bezine, M., Karym, E. M., Badreddine, A., Rouaud, O., Moreau, T., Cherkaoui-Malki, M., El Ayeb, M., Nasser, B., et al. (2018) · Current Alzheimer Research · doi:10.2174/1567205014666170505101426 · Cited by 170
Neuroimmunomodulation in the Pathogenesis of Alzheimer’s Disease
Morales, I., Farías, G., & Maccioni, R. B. (2010) · Neuroimmunomodulation · doi:10.1159/000258724 · Cited by 162
Self-citation
Tau Oligomers and Fibrils Induce Activation of Microglial Cells
Morales, I., Jiménez, J. M., Mancilla, M., & Maccioni, R. B. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-131843 · Cited by 160
Self-citation
Clinical aspects of inflammation in Alzheimer's disease
Rosenberg, P. B. (2005) · International Review of Psychiatry · doi:10.1080/02646830500382037 · Cited by 158
Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects
Nagaraj, S., Laskowska-Kaszub, K., Dębski, K. J., Wojsiat, J., Dąbrowski, M., Gabryelewicz, T., Kuźnicki, J., & Wojda, U. (2017) · Oncotarget · doi:10.18632/oncotarget.15109 · Cited by 148
Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer’s Disease
Yang, C., Chiu, M., Chen, T., Chang, H.-L., Liu, B.-H., & Yang, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170810 · Cited by 143
Selective Interaction of Lansoprazole and Astemizole with Tau Polymers: Potential New Clinical Use in Diagnosis of Alzheimer's Disease
Rojo, L. E., Alzate‐Morales, J. H., Saavedra, I. N., Davies, P., & Maccioni, R. B. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1262 · Cited by 141
Self-citation
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136
Injury markers predict time to dementia in subjects with MCI and amyloid pathology
van Rossum, I. A., Vos, S. J. B., Burns, L., Knol, D. L., Scheltens, P., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182704056 · Cited by 136
Potential Inflammatory biomarkers in Alzheimer's disease
Mrak, R. E., & Griffin, W. S. T. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8406 · Cited by 135
Altered Amyloid Protein Processing in Platelets of Patients With Alzheimer Disease
Rosenberg, R. N., Baskin, F., Fosmire, J. A., Risser, R. C., Adams, P., Svetlik, D. A., Honig, L. S., Cullum, C. M., & Weiner, M. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550140019007 · Cited by 124
Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
Dunys, J., Valverde, A., & Checler, F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r118.003999 · Cited by 120
Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
Lue, L., Guerra, A., & Walker, D. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0074-8 · Cited by 116
A Method for Diagnosing Alzheimer’s Disease Based on Salivary Amyloid-β Protein 42 Levels
Lee, M., Guo, J., Kennedy, K., McGeer, E. G., & McGeer, P. L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160748 · Cited by 114
Platelet APP isoform ratios correlate with declining cognition in AD
Baskin, F., Rosenberg, R. N., Iyer, L., et al. (2000) · Neurology · doi:10.1212/wnl.54.10.1907 · Cited by 113
Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer’s disease
Maes, M. H. J., Devos, N., Wauters, A., Demedts, P., Maurits, V., Neels, H. M., Bosmans, E., Altamura, C. A., Lin, A., Song, C., et al. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00016-3 · Cited by 110
Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Hedrick, S., Pappas, V., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.06.001 · Cited by 108
Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
Andréasson, U., Blennow, K., & Zetterberg, H. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.05.005 · Cited by 98
Abnormalities in the Pattern of Platelet Amyloid Precursor Protein Forms in Patients With Mild Cognitive Impairment and Alzheimer Disease
Padovani, A., Borroni, B., Colciaghi, F., Pettenati, C., Cottini, E., Agosti, C., Lenzi, G. L., Caltagirone, C., Trabucchi, M., Cattabeni, F., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.1.71 · Cited by 96
Human Platelets Tau: A Potential Peripheral Marker for Alzheimer's Disease
Neumann, K., Farias, G. A., Slachevsky, A., Perez, P., & Maccioni, R. B. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101641 · Cited by 95
Self-citation
Pitfalls and Limitations of PET/CT in Brain Imaging
Salmon, É., Bernard, C., & Hustinx, R. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.03.008 · Cited by 90
Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer’s Disease and Parkinson’s Disease Dementia?
Femminella, G. D., Ninan, S., Atkinson, R., Fan, Z., Brooks, D. J., & Edison, P. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150827 · Cited by 88
β‐Amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon ‐γ and ‘advanced glycation endproducts’ in a murine microglia cell line
Gasic‐Milenkovic, J., Dukic‐Stefanovic, S., Deuther‐Conrad, W., Gärtner, U., & Münch, G. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02506.x · Cited by 87
The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease
Clark, L. F., & Kodadek, T. J. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00042 · Cited by 83
Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer’s disease: a systematic review
Ruan, Q., D’Onofrio, G., Sancarlo, D., Bao, Z., Greco, A., & Yu, Z. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0281-7 · Cited by 83
Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept
Epelbaum, S., Genthon, R., Cavedo, E., Habert, M. O., Lamari, F., Gagliardi, G. P., Lista, S., Teichmann, M., Bakardjian, H., Hampel, H. J., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.003 · Cited by 82
Postmortem Brain, Cerebrospinal Fluid, and Blood Neurotrophic Factor Levels in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Du, Y., Wu, H., Qin, X., Cao, C. Q., Liu, Y., Cao, Z.-Z., & Cheng, Y. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1100-8 · Cited by 80
The Damage Signals Hypothesis of Alzheimer's Disease Pathogenesis
Fernández, J. A., Rojo, L. E., Kuljiš, R. O., & Maccioni, R. B. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14307 · Cited by 77
Self-citation
Role of the JAKs/STATs pathway in the intracellular calcium changes induced by interleukin-6 in hippocampal neurons
Orellana, D. I., Quintanilla, R. A., Gonzalez-Billault, C., & Maccioni, R. B. (2005) · Neurotoxicity Research · doi:10.1007/bf03033983 · Cited by 76
Self-citation
Pharmacologic Approaches to the Treatment of Amyotrophic Lateral Sclerosis
McGeer, E. G., & McGeer, P. L. (2005) · BioDrugs · doi:10.2165/00063030-200519010-00004 · Cited by 75
Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients
März, P., Heese, K., Höck, C., Golombowski, S., Müller-Spahn, F., Rose‐John, S., & Otten, U. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00886-0 · Cited by 74
Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type
Engelborghs, S., Brabander, M. D., Crée, J. D., D’Hooge, R., Geerts, H., Verhaegen, H., & Deyn, P. P. D. (1999) · Neurochemistry International · doi:10.1016/s0197-0186(99)00031-5 · Cited by 69
Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients
Wada‐Isoe, K., Wakutani, Y., Urakami, K., & Nakashima, K. (2004) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2004.00286.x · Cited by 69
Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects
Maccioni, R. B., Manuel Lavados, M., Guillón, M., Mújica, C. L. D., BOSCH, R., FARIAS, G., & FUENTES, P. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.01.011 · Cited by 68
Self-citation
CSF p-Tau levels in the prediction of Alzheimer's disease
Kandimalla, R. J. L., Prabhakar, S. K., Wani, W. Y., Kaushal, A., Gupta, N., Sharma, D. R., Grover, V., Bhardwaj, N., Jain, K., & Gill, K. D. (2013) · Biology Open · doi:10.1242/bio.20135447 · Cited by 68
Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
Bibl, M., Gallus, M., Welge, V., Esselmann, H., Wolf, S., Rüther, E., & Wiltfang, J. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0801-3 · Cited by 65
Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline
Nettiksimmons, J., Harvey, D. J., Brewer, J. B., Carmichael, O. T., DeCarli, C. S., Jack, C. R., Petersen, R. C., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.025 · Cited by 64
Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis
Rowe, C. C., & Villemagne, V. L. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.017 · Cited by 62
Platelet Amyloid Precursor Protein Abnormalities in Mild Cognitive Impairment Predict Conversion to Dementia of Alzheimer Type
Borroni, B., Colciaghi, F., Caltagirone, C., Rozzini, L., Broglio, L., Cattabeni, F., Luca, M. D., & Padovani, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1740 · Cited by 61
Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease
Hampel, H. J., Schoen, D., Schwarz, M., Kötter, H. U., Schneider, C., Sunderland, T., Dukoff, R. A., Levy, J., Padberg, F., Stübner, S., et al. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00379-0 · Cited by 59
Mechanisms of Tau Self-Aggregation and Neurotoxicity
Farias, G. A., Cornejo, A., Jimenez, J., Guzmán, L., & Maccioni, R. B. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717258 · Cited by 55
Self-citation
Platelet Tau Pattern Correlates with Cognitive Status in Alzheimer's Disease
Farias, G. A., Pérez, P., Slachevsky, A., & Maccioni, R. B. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120304 · Cited by 54
Self-citation
Nutraceuticals: A Novel Concept in Prevention and Treatment of Alzheimer's Disease and Related Disorders
Farias, G. A., Guzmán‐Martínez, L., Delgado, C., & Maccioni, R. B. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132741 · Cited by 52
Self-citation
Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities
Parent, M. J., Zimmer, E. R., Shin, M., Kang, M. S., Fonov, V., Mathieu, A. P., Aliaga, A., Kostikov, A. P., Carmo, S. D., Dea, D., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1346-17.2017 · Cited by 51
Aging-Related Changes in Cognition and Cortical Integrity are Associated With Serum Expression of Candidate MicroRNAs for Alzheimer Disease
Maldonado, I. C., Atienza, M., Sanchez-Espinosa, M. P., & Cantero, J. L. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy323 · Cited by 49
Increased cytosolic free calcium in lymphocytes of Alzheimer patients
Adunsky, A., Baram, D., Hershkowitz, M., et al. (1991) · Journal of Neuroimmunology · doi:10.1016/0165-5728(91)90060-k · Cited by 48
Added Diagnostic Value of 11C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis
Frederiksen, K. S., Hasselbalch, S. G., Hejl, A., Law, I. G., Højgaard, L. D., & Waldemar, G. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000345783 · Cited by 46
Biological Markers of Alzheimers Disease and Mild Cognitive Impairment
Maccioni, R. B., Manuel Lavados, M., Maccioni, C., & Mendoza‐Naranjo, A. (2004) · Current Alzheimer Research · doi:10.2174/1567205043332018 · Cited by 43
Self-citation
Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Kandimalla, R. J. L., Prabhakar, S., Binukumar, B. K., Wani, W. Y., Gupta, N., Sharma, D. R., Sunkaria, A., Grover, V., Bhardwaj, N., Jain, K., et al. (1970) · Current Alzheimer Research · doi:10.2174/156720511795256071 · Cited by 43
Relation of Plasma Homocysteine to Plasma Amyloid Beta Levels
Luchsinger, J. A., Tang, M.-X., Miller, J. W., Green, R., Mehta, P. D., & Mayeux, R. P. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9207-7 · Cited by 43
Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer’s Disease
Slachevsky, A., Guzmán‐Martínez, L., Delgado, C., Reyes, P. A., Farias, G. A., Muñoz‐Neira, C., Bravo, E., Farías, M., Flores, P., Cristián Garrido, I., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160652 · Cited by 40
Self-citation
Loss of Neuroprotective Factors in Neurodegenerative Dementias: The End or the Starting Point?
Benussi, L., Binetti, G. G., & Ghidoni, R. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00672 · Cited by 35
ApoE Alleles and Tau Markers in Patients with Different Levels of Cognitive Impairment
Manuel Lavados, M., Farias, G. A., Rothhammer, F., Guillón, M., Mujica, M. V., Maccioni, C., & Maccioni, R. B. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.03.036 · Cited by 32
Self-citation
CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease
Kandimalla, R. J. L., Anand, R., Veeramanikandan, R., Wani, W. Y., Prabhakar, S. K., Grover, V. K., Bharadwaj, N., Jain, K., & Gill, K. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140331161027 · Cited by 32
Temporal Integrative Analysis of mRNA and microRNAs Expression Profiles and Epigenetic Alterations in Female SAMP8, a Model of Age-Related Cognitive Decline
Cosín‐Tomás, M., Álvarez‐López, M. J., Companys‐Alemany, J., Kaliman, P., González-Castillo, C., Ortuño‐Sahagún, D., Pallàs, M., & Griñán‐Ferré, C. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00596 · Cited by 31
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients
Baskin, F., Rosenberg, R. N., Fang, X. T., Hynan, L. S., Moore, C. B., Weiner, M., & Vega, G. L. (2003) · Neurology · doi:10.1212/01.wnl.0000068029.56740.96 · Cited by 30
Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease
Zvěřová, M., Kitzlerová, E., Fišar, Z., et al. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666180601090533 · Cited by 28
Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients
Kandimalla, R. J. L., Prabhakar, S., Binukumar, B. K., Wani, W. Y., Sharma, D. R., Grover, V., Bhardwaj, N., Jain, K., & Gill, K. D. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.06.075 · Cited by 26
Emerging Noninvasive Biomarkers for Early Detection of Alzheimer's Disease
Guzmán‐Martínez, L., Farias, G. A., & Maccioni, R. B. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.013 · Cited by 23
Self-citation
Biomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations
Cummings, J. L., & Zhong, K. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.205 · Cited by 21
Introductory Remarks
Maccioni, R. B. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.11.001 · Cited by 11
Self-citation
N-truncated Aβ peptides in complex fluids unraveled by new specific immunoassays
Ranaldi, S., Caillava, C., Promé, S., Rubrecht, L., Cobo, S., Salvetat, N., Paty, E. D., Galéa, P., Aldrian, G., Le‐Nguyen, D., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.05.016 · Cited by 10
Cerebrospinal fluid inflammatory markers in amnestic mild cognitive impairment
Rizzi, L., & Roriz‐Cruz, M. (2016) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12704 · Cited by 9
Application value of serum biomarkers for choosing memantine therapy for moderate AD
Wei, H., Zhu, X., & Li, Y. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8926-4 · Cited by 7
Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?
Rojo, L. E., Gaspar, P. A., & Maccioni, R. B. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717203 · Cited by 6
Self-citation

Research works printed but not linked: 17

Alzheimar A. Psychiatr Psych gericht Med, Über eine eigenartige Erkrankung der Hirnrinde.,, , 64,, 146-8,1907
Maccioni RB, Perry G. Current Hypotheses and Research Milestones in Alzheimer's Disease New York: Springer Science+Bussiness Media, LLC;, ,, , 17,, 3-241,(2009)
. Alzheimer's , Association As 2018 Alzheimer’s disease facts and figures.,, , 14,, 367-429,(2018)
Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L. J Med Assoc, Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer’s disease (AD) and other dementia at Siriraj Hospital, Thailand.,, , 94,, S77-S83,(2011)
Sohma H, Kokai Y. Update on Dementia: InTech, ,, (2016), 8,, 67-83,
McGhee DJ, Ritchie CW, Thompson PA, Wright DE, Zajicek JP, Counsell CE. PLoS One, A systematic review of biomarkers for disease progression in Alzheimer’s disease.,, , 9,, 1809-,(2014)
Sjodin S, Hansson O, Ohrfelt A, Brinkmalm G, Zetterberg H, Brinkmalm A. Proteom Clin App, Mass spectrometric analysis of cerebrospinal fluid ubiquitin in Alzheimer's disease and Parkinsonian disorders.,, , 11,, 340-,(2017)
Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. The Cochrane Database Syst Rev, CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI).,, , 3,, 454-,(2017)
Rojo L, Sjoberg MK, Hernandez P, Zambrano C, Maccioni RB. J Biomed Biotechnol, Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer’s disease.,, , 2006,, 73976-,(2006)
Borroni B, Colciaghi F, Pastorino L, Pettenati C, Cottini E, Rozzini L. Arch Neurol, Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.,, , 58,, 442-446,(2001)
Martinez B, Peplow PV. Neural Regen Res, MicroRNAs as diagnostic and therapeutic tools for Alzheimer’s disease: advances and limitations.,, , 14,, 242-255,(2019)
Chang WS, Wang YH, Zhu XT, Wu CJ. Med Sci, Genome-wide profiling of miRNA and mRNA expression in Alzheimer’s disease.,, , 23,, 2721-2731,(2017)
Morales I, Guzman-Martinez L, Cerda-Troncoso C, Farias GA, Maccioni RB. Front Cell Neurosci, Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches.,, , 8,, 112-,(2014)
Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernandez J, Campos-Pena V. Front Integr Nuerosci, Inflammatory process in Alzheimer’s Disease.,, , 7,, 59-,(2013)
Nuzzo D, Picone P, Caruana L, Vasto S, Barera A, Caruso C. Inflammation, Inflammatory mediators as biomarkers in brain disorders.,, , 69,, 639-648,(2014)
Mosconi L. Clin Trans Imag, Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies.,, , 1,, 1419-,(2013)
Perani D, Schillaci O, Padovani A, Nobili FM, Iaccarino L, Della Rosa PA. BioMed Res Int, A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis.,, , 2014,, 1419-,(2014)

Sorted by citations

Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2023) · Cells · doi:10.3390/cells12091309 · Cited by 309
Novel Nutraceutical Compounds in Alzheimer Prevention
Maccioni, R. B., Calfío, C., González, A., & Lüttges, V. (2022) · Biomolecules · doi:10.3390/biom12020249 · Cited by 45
Self-citation

See all 87

Authors: Guzman-Martinez, L., Maccioni, R. B., Farías, G. A., Fuentes, P., & Navarrete, L. P.
Affiliations: Faculty of Sciences, University of Chile, Santiago, Chile
University of Chile (CL)
Clinical Hospital, University of Chile, Santiago, Chile
Hospital Clínico de la Universidad de Chile (CL)
Corresponding author: Maccioni, Ricardo B.
ORCID: Maccioni, Ricardo B.
Fuentes, Patricio
Venue: Current Alzheimer Research
Publisher: Bentham Science Publishers Ltd.
Published: 2019-07-23
Volume: 16
Issue: 6
Pages: 518-528
ISSN: 1567-2050 (ISSN-L)
DOI: 10.2174/1567205016666190517121140
OpenAlex: W3098965555
Cited by: 87
References: 101
Citations by year: 2026: 1 · 2025: 13 · 2024: 17 · 2023: 18 · 2022: 20 · 2021: 4 · 2020: 12 · 2019: 2
FWCI: 1.12
Type: journal article
Language: en
Open access: closed
Locations: Current Alzheimer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, biomarkers, early diagnosis, cerebrospinal fluid, hyperphosphorylated tau, amyloid-beta, positron emission tomography, blood biomarkers, neuroinflammation, synaptic dysfunction, neurodegeneration, brain atrophy, cognitive decline
MeSH terms: Alzheimer Disease, Humans, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Biomarkers for Alzheimer’s Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks